AU2002359401A1 - Anti-estrogen and immune modulator combinations for treating breast cancer - Google Patents
Anti-estrogen and immune modulator combinations for treating breast cancerInfo
- Publication number
- AU2002359401A1 AU2002359401A1 AU2002359401A AU2002359401A AU2002359401A1 AU 2002359401 A1 AU2002359401 A1 AU 2002359401A1 AU 2002359401 A AU2002359401 A AU 2002359401A AU 2002359401 A AU2002359401 A AU 2002359401A AU 2002359401 A1 AU2002359401 A1 AU 2002359401A1
- Authority
- AU
- Australia
- Prior art keywords
- estrogen
- breast cancer
- immune modulator
- treating breast
- modulator combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 229940046836 anti-estrogen Drugs 0.000 title 1
- 230000001833 anti-estrogenic effect Effects 0.000 title 1
- 239000000328 estrogen antagonist Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33280101P | 2001-11-14 | 2001-11-14 | |
| US60/332,801 | 2001-11-14 | ||
| PCT/US2002/036633 WO2003041654A2 (en) | 2001-11-14 | 2002-11-13 | Anti-estrogen and immune modulator combinations for treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002359401A1 true AU2002359401A1 (en) | 2003-05-26 |
Family
ID=23299909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002359401A Abandoned AU2002359401A1 (en) | 2001-11-14 | 2002-11-13 | Anti-estrogen and immune modulator combinations for treating breast cancer |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1515748A4 (en) |
| AU (1) | AU2002359401A1 (en) |
| WO (1) | WO2003041654A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150099A1 (en) * | 2011-12-16 | 2015-01-30 | Olema Pharmaceuticals Inc | NOVELTY BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES OF THEM |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2558373B1 (en) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | ANTI-ESTROGEN MEDICINAL PRODUCT BASED ON 4-HYDROXYTAMOXIFENE FOR PERCUTANEOUS ADMINISTRATION |
| US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
| US6261787B1 (en) * | 1996-06-03 | 2001-07-17 | Case Western Reserve University | Bifunctional molecules for delivery of therapeutics |
| AU2001272908A1 (en) * | 2000-05-10 | 2001-11-20 | David A. Sirbasku | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
-
2002
- 2002-11-13 WO PCT/US2002/036633 patent/WO2003041654A2/en not_active Ceased
- 2002-11-13 EP EP02793936A patent/EP1515748A4/en not_active Withdrawn
- 2002-11-13 AU AU2002359401A patent/AU2002359401A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1515748A2 (en) | 2005-03-23 |
| WO2003041654A3 (en) | 2005-01-06 |
| EP1515748A4 (en) | 2006-04-12 |
| WO2003041654A2 (en) | 2003-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251270A0 (en) | Cancer treatment | |
| AU2002212527A1 (en) | Thermometry-based breast cancer risk assessment | |
| AU2002362454A1 (en) | Regulated breast cancer genes | |
| AU5047800A (en) | Breast, gastric and prostate cancer associated antigens and uses therefor | |
| EP1372736A4 (en) | Anti-neovasculature preparations for cancer | |
| EP1176964B8 (en) | Uses of et743 for treating cancer | |
| AUPQ923100A0 (en) | Treatment of prostate cancer | |
| AU2002351374A1 (en) | Antibodies to treat cancer | |
| AU2002313426A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| AU2002308642A1 (en) | Methods for treating cancer | |
| AU2001257325A1 (en) | Cancer treatment | |
| AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer | |
| AU2002359401A1 (en) | Anti-estrogen and immune modulator combinations for treating breast cancer | |
| GB0026015D0 (en) | Cancer treatment | |
| AU5552400A (en) | Treatment of cancer | |
| AUPQ367699A0 (en) | Treatment of cancer | |
| AU2002331816A1 (en) | A cancer treatment system | |
| AU2002305138A1 (en) | Methods and materials for cancer treatment | |
| AU5632500A (en) | Cancer associated antigens and uses therefor | |
| AU2292801A (en) | Compositions and methods for treatment of breast cancer | |
| AU5097099A (en) | Methods and compositions for cancer treatment | |
| AU2002366364A1 (en) | E2f and cancer therapy | |
| AU2001289127A1 (en) | Tumor treatment | |
| AU2002351382A1 (en) | Combination cancer therapy | |
| AU2453399A (en) | Bone cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |